Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LAA-START

Financiado

Left Atrial Appendage Electrical Isolation via Bio photonic Optical Confirmation...

Left Atrial Appendage Electrical Isolation via Bio photonic Optical Confirmation to Treat Persistent Atrial Fibrillation Atrial Fibrillation (AF) is an irregular heartbeat caused by abnormal electrical activity in the heart, that can lead to blood clots with high risk of stroke and heart failure. There are 10.7 million AF patients across Europe and... ver más

31/03/2022

AURIGEN MEDICAL LI...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

AURIGEN MEDICAL LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-03-31

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 60% 100%

6 Participantes

AURIGEN MEDICAL LIMITED

1.12M€ | Lider

TAHE PRODUCTOS COSMETICOS

366.90K€ | Participante

Tele

953.47K€ | Participante

CVUT

79.52K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 39 meses Fecha Inicio: 2018-12-14
Fecha Fin: 2022-03-31

Líder del proyecto

AURIGEN MEDICAL LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Descripción del proyecto Atrial Fibrillation (AF) is an irregular heartbeat caused by abnormal electrical activity in the heart, that can lead to blood clots with high risk of stroke and heart failure. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF), they are highly symptomatic and medication resistant. Surgical electrical therapy (catheter ablation) destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart the Left Atrial Appendage (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, occlusion devices fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients. AuriGen Medical have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. This multi-partner FTI project will complete product development in line with the regulatory development pathway for medical devices for first in human safety and efficacy clinical studies required for CE certification and contributing to FDA clinical data requirements. The total market opportunity is $5bn/yr market opportunity across the EU and US. AuriGen will enter the market directly in the initial target European markets (Germany, France, Italy and UK) during Q3 2020.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores